摘要
目的探讨血管内皮生长因子受体(Flk-1)、肺耐药蛋白(LRP)基因在非小细胞肺癌(NSCLC)中表达的临床意义。方法用免疫组化技术(ABC法)对NSCLCs组织中两种基因的表达进行检测。结果NSCLCs患者LRP表达率为69.5%(41/59),其中腺癌明显高于鳞癌(P<0.05)。LRP与Flk-1在59例NSCLCs中共同表达29例(49.2%),LRP的表达与肺癌的组织学分级及组织学类型有关,Flk-1与TNM分期相关,均有统计学意义(P<0.05)。Flk-1+LRP、复发与患者的生存率有关(P<0.05)。结论Flk-1和LRP基因蛋白产物的检测对肺癌患者的诊治和预后评估有积极意义。
Objective To investigate the effect of Flk-1, LRP genes in the carcinogenesis and development of non-small cell lung carcinoma（NSCLC）. Method The expression of Flk-1, LRP geneproteins in NSCLCs were studied immunohistochemically. Results Of the 59 NSCLCs, 41 （69.5 % ） were overexpression for LRP. The squamouscarcinoma was significantly different from aclenocarcinoma in the positive rate of LRP（P 〈 0.05）. The co-expression rate of LRP with Flk-1 in 59 cases of NSCLCs was 49.2 %. There was significant correlation between the expression of LRP and histological grade and histological type and the expression of Flk-1 and TNM staging too （P 〈 0.05）. In a multivariate analysis by Cox regression model, the overexpression of Flk-1 ＋ LRP and recrudescence were independently associated with patient survival length（P 〈 0.05）. Conclusion The detection of Flk-1 and LRP geneproteins has positive effects on diagnosis, prognosis and treatment of lung tumors.
出处
《苏州大学学报（医学版）》
CAS
北大核心
2005年第4期635-637,共3页
Suzhou University Journal of Medical Science
